Astrana Healthの空売り状況は、投資家がAstrana Healthの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Astrana Health (NASDAQ:ASTH) 株価情報, 空売り情報

Astrana Health

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

Astrana Health Inc

TAOP

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) has outperformed the market over the past 10 years by 6.9% on an annualized basis producing an average annual return of 17.66%. Currently, PulteGroup has a market capitalization of $19.58 billion. 
Buying $1000 In PHM: If an investor had bought $1000 of PHM stock 10 years ago, it would be worth $5,070.58 today based on a price of $97.71 for PHM at the time of writing.
<h3>PulteGroup's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748475911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In PulteGroup 10 Years Ago Would Be Worth This Much Today

Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) has outperformed the market over the past 10 years by 9.06% on an annualized basis producing an average annual return of 19.83%. Currently, Wix.com has a market capitalization of $8.48 billion. 
Buying $100 In WIX: If an investor had bought $100 of WIX stock 10 years ago, it would be worth $612.14 today based on a price of $152.30 for WIX at the time of writing.
<h3>Wix.com's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748475011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Wix.com 10 Years Ago Would Be Worth Today

Restaurant company Steak ‘n Shake is a sponsor of the Bitcoin 2025 Conference and used the event to share an update on its recent push into Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as a payment option, as it also embraced the crypto community via <a href="https://www.benzinga.com/general/restaurants/25/05/45328334/steak-n-shake-goes-steaktoshi-embraces-bitcoin-maga-culture-tesla-fanbase">social media posts.</a>
What Happened: While many in attendance at the Bitcoin 2025 Conference in Las Vegas may have been excited to hear from U.S. Vice President JD Vance who talked about<a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45652549/vice-president-jd-vance-predicts-100m-bitcoin-holders-the-us-ought-to-be-leaning-into-bitcoin"> the growing adoption</a> of Bitcoin in the country, others may have loved a real-world example from Steak ‘n Shake.
The restaurant company, which is owned by Biglari Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BH#NYSE">BH</a>), launched Bitcoin payments on May 16 utilizing the Bitcoin Lightning Network.
Steak ‘n Shake Chief Operations Officer Dan Edwards spoke at the Bitcoin event about the company's push into crypto.
"The day we launched Bitcoin, one out of every 500 bitcoin transactions in the world happened at Steak ‘n Shake," Edwards said, calling the Bitcoin payment acceptance at locations "a global implementation."
In the speech, Edwards said that accepting Bitcoin as a payment option was not a publicity stunt, as <a href="https://bitcoinmagazine.com/news/steak-n-shake-reveals-bitcoin-payment-success-at-bitcoin-2025-conference">reported </a>by Bitcoin Magazine.
"We didn't see this as a marketing gimmick. We saw it as a viable option to pay — on par with other globally accepted methods.
Edwards said Bitcoin is helping the company with transaction speeds and the company is saving 50% in processing fees.
"That makes Bitcoin a win for the customer, a win for us, and a win for the Bitcoin community."
Edwards said since the restaurant company started accepting Bitcoin as a payment option, it saw increased sales.
"We've seen a sustained spike since adding Bitcoin."
Posts on social media highlighted the company's Bitcoin payment options with a call out to the crypto community by some large accounts to try and support the restaurant.
Among the supporters was Bitcoin advocate and Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) CEO Jack Dorsey. A user on X <a href="https://x.com/SteaknShake/status/1923387257190306055">told </a>Dorsey it was a shame that Steak ‘n Shake wasn't using Block's Square terminals.  
"We are going to work on that," Dorsey said.
Read Also: <a href="https://www.benzinga.com/25/03/44419119/making-kennedy-proud-again-new-poll-shows-34-of-diners-more-likely-to-try-food-cooked-in-beef-tallow">Making Kennedy Proud Again? New Poll Shows 34% Of Diners More Likely To Try Food Cooked In Beef Tallow</a>
Why It's Important: Steak ‘n Shake has <a href="https://www.benzinga.com/general/restaurants/25/03/44280041/rfk-jr-thanks-steak-n-shake-for-rfking-the-french-fries-restaurant-goes-all-in-on-make-america-healthy-again">embraced several communities </a>in recent months, including Tesla fans, and investors and fans of President Donald Trump, Secretary of Health and Human Services Robert F. Kennedy Jr. and the "Make America Healthy Again" movement.
The restaurant received increased attention for switching its cooking method for French fries to beef tallow, which drew praise and a visit from Kennedy.
Embracing these communities and a social media push that appeals to these fans could help with sales and ultimately help Biglari&#8217;s stock.
Edwards said the company offered several limited-edition Bitcoin-themed menu items in Las Vegas to celebrate the Bitcoin launch. This includes the Bitcoin Burger, a Bitcoin Milkshake and a Super-Sized Bitcoin Meal.
The restaurant executive also teased that a "blockchain menu" is in the works.
As for what Steak ‘n Shake could be embracing next, artificial intelligence could be the answer.
"We're not done. We're investing in cyber chefs, autonomous drives, AI tech — and we need engineers to help us build it."
BH Price Action: Biglari Holdings stock closed down 2.34% to $261.07 on Wednesday versus a 52-week trading range of $159.69 to $271.35. Biglari stock is up 2.7% year-to-date and up 34% over the last year.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/02/44059763/rfk-jr-applauds-this-restaurant-chains-move-fries-will-be-rfkd">RFK Jr Applauds This Restaurant Chain&#8217;s Move: &#8216;Fries Will Be RFK&#8217;D&#8217;</a></li>
</ul>
Photo: Deutschlandreform via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Restaurants

$BTC

Steak 'N Shake Thanks Bitcoin For Higher Sales, Lower Fees — And It's Celebrating With 'Blockchain Menu'

Economics

Trump's Global Tariffs Blocked By U.S. Trade Court

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 20 years by 2.57% on an annualized basis producing an average annual return of 10.84%. Currently, Stryker has a market capitalization of $145.19 billion. 
Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 20 years ago, it would be worth $7,775.76 today based on a price of $380.39 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748474116_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Stryker 20 Years Ago Would Be Worth Today

Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) has outperformed the market over the past 15 years by 1.41% on an annualized basis producing an average annual return of 13.18%. Currently, Starbucks has a market capitalization of $97.96 billion. 
Buying $100 In SBUX: If an investor had bought $100 of SBUX stock 15 years ago, it would be worth $647.10 today based on a price of $86.20 for SBUX at the time of writing.
<h3>Starbucks's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748473212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SBUX

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

BIMA, a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-native DeFi platform, has partnered with exSat Network to advance the use of Bitcoin in decentralized finance. 
The collaboration kicks off with an initial $100 million deployment, equivalent to 1,000 BTC, towards enabling permissionless yield strategies. 
The two firms also revealed an option to scale the capital allocation to $500 million (5,000 BTC) as demand grows.
The alliance positions BIMA as the official stablecoin provider across the exSat ecosystem, integrating its overcollateralized USBD stablecoin with exSat-native assets like esBTC and iBTC. 
This deployment is aimed at allowing Bitcoin holders to tap into DeFi yields without selling their assets or exiting the Bitcoin standard.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45654053/blackrock-to-take-10-stake-in-circles-ipo">BlackRock To Take 10% Stake In Circle&#8217;s IPO</a>
"This partnership with exSat marks a major step towards mobilizing Bitcoin as a productive asset in DeFi," said BIMA CEO Sid Sridhar. "We're building the infrastructure to enable secure, capital-efficient deployment of USBD across DeFi and CeFi."
The collaboration comes shortly after BIMA's mainnet launch, which introduced tools for both institutional and retail investors to borrow against Bitcoin and access structured yield products. 
Users can mint USBD stablecoins through an integrated platform that supports major wallets such as Ledger, MetaMask, and XVerse.
exSat Founder Yves La Rose emphasized the long-term vision of unlocking new use cases for Bitcoin as block rewards decline. 
"This collaboration brings us one step closer to building a sovereign Bitcoin banking layer," he said. "By enabling users to borrow USBD against BTC and access permissionless yield, we're expanding Bitcoin's utility without forcing users to sell."
Both teams aim to address a critical gap in Bitcoin's current functionality: the ability to generate yield natively, without compromising on-chain security or decentralization principles.
Read Next: • <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45652549/vice-president-jd-vance-predicts-100m-bitcoin-holders-the-us-ought-to-be-leaning-into-bitcoin">Vice President JD Vance Predicts 100M Bitcoin Holders: &#8216;The US Ought To Be Leaning Into Bitcoin&#8217;</a>
Photo: Shutterstock

BIMA, exSat Launch $100M Initiative To Expand Bitcoin-Backed DeFi Infrastructure

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 6.26% on an annualized basis producing an average annual return of 20.05%. Currently, Insmed has a market capitalization of $12.09 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 5 years ago, it would be worth $265.55 today based on a price of $66.36 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748472314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INSM

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) has outperformed the market over the past 5 years by 20.61% on an annualized basis producing an average annual return of 34.4%. Currently, KLA has a market capitalization of $104.32 billion. 
Buying $100 In KLAC: If an investor had bought $100 of KLAC stock 5 years ago, it would be worth $441.86 today based on a price of $785.00 for KLAC at the time of writing.
<h3>KLA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748471411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KLAC

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Sen. Bernie Sanders (I-VT) took a jab at President Donald Trump on social media, mocking a recent claim and executive order Trump made about slashing drug prices.
&#8220;Good news: Donald Trump, who never lies, just announced he alone has reduced drug prices by 85%,&#8221; Sanders <a href="https://x.com/SenSanders/status/1924887208919507090">posted on X</a> on May 20. &#8220;Quick. Go to your pharmacy. Demand an 85% reduction on your drug prices. Tell them Trump sent you.&#8221;&nbsp;
He also added, &#8220;If that doesn't work, tell him to support the bill I&#8217;m introducing that&#8217;ll do it.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
<h2 class="wp-block-heading">Trump's Latest Executive Order on Drug Prices</h2>
Sanders&#8217; post came days after Trump signed an <a href="https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/">executive order</a> on May 12 aimed at lowering prescription drug costs for Americans. The order focuses on ensuring Americans pay the same or less than other wealthy nations by pressuring pharmaceutical companies to offer &#8220;Most-Favored-Nation&#8221; pricing—the lowest price they offer to any developed country.
According to a White House <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">fact sheet</a>, the order allows Americans to buy drugs directly from manufacturers, <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">bypassing middlemen</a>. If companies don't cooperate, the Department of Health and Human Services is instructed to take aggressive regulatory steps.
&#8220;Our citizens pay massively higher prices than other nations for the same exact pill,&#8221; Trump said. &#8220;We would spend tremendous amounts of money in order to provide inexpensive drugs to another country.&#8221;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Backing up both arguments is a February 2024 Rand Corp. <a href="https://www.rand.org/news/press/2024/02/01.html">study</a> that found U.S. drug prices are on average 2.78 times higher than in 33 other developed nations. For brand-name drugs, the gap is even wider—4.22 times higher.
The Rand report also revealed that in 2022, the U.S. accounted for 62% of global drug sales, despite making up just 24% of total prescription volume.
Meanwhile, <a href="https://www.benzinga.com/personal-finance/25/04/45029761/experts-warn-tariffs-could-negatively-impact-pretty-fragile-supply-of-generic-drugs">generics in the U.S.</a> cost less than abroad, averaging about 67% of international prices.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Who's Really Paying?&nbsp;</h2>
The Trump administration argues Americans are subsidizing both Big Pharma and foreign health systems, while Sanders wants broader government action to force lower prices through legislation.
During a <a href="https://www.youtube.com/watch?v=6EHXakUFBs4">briefing</a> on the Make America Healthy Again Commission's report on children's health, Trump criticized other countries for negotiating harder on prices, calling their representatives &#8220;a lot more vicious than us,&#8221; and argued that the U.S. has been footing the bill for lower drug prices overseas for years.
"We are going to now get a reduction in drug costs of up to 89% in some cases, but 50% would be a low, a bad number," Trump said. "It's going to be massive numbers. It's going to be incredible for Medicaid, incredible for all forms of health care. Medicare is going to be; it's going to have a huge impact, so big that nobody can calculate it."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Bernie Sanders Says, 'Trump Just Announced He's Reduced Drug Prices By 85%,' Dares You To Go To The Pharmacy And 'Tell Them Trump Sent You'

Retailer Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) could provide a look at consumer spending and tariffs when the company reports third-quarter financial results Thursday <a href="https://www.benzinga.com/earnings">after market close.</a>
Here is a look at the analyst estimates, what analysts are saying before the results and key items to watch.
Earnings Estimates: Analysts expect Costco to report third-quarter revenue of $63.19 billion, up from $58.52 billion in last year's third quarter according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0528">from Benzinga Pro.</a>
The company beat revenue estimates in the second quarter, but has only beaten analyst estimates in four of the last 10 quarters overall.
Analysts expect Costco to report third-quarter earnings per share of $4.24, up from $3.78 in last year's third quarter. The company has missed analyst estimates for earnings per share in two straight quarters, while beating estimates in seven of the last 10 quarters overall.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/05/45335286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-64">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a>
What Analysts Are Saying: After a strong<a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45298451/jpmorgan-sees-more-upside-for-costco-as-us-sales-e-commerce-outperform"> April sales figure</a> from Costco, JPMorgan analyst Christopher Horvers reiterated an Overweight rating and raised the price target from $1,070 to $1,088.
The analyst said the 7.1% U.S. core comparable sales growth in April was ahead of estimates, despite a calendar-related sales headwind from the Easter timing shift.
The month of April also saw the average transaction size up 2.4% year-over-year and e-commerce sales growth of 13% year-over-year.
Along with the positives were several negatives, including weaker sales in Canada and international markets and less early demand in April for non-food items compared to March.
Horvers said Costco has strong global momentum, is seeing market share gains and has exposure to a potential rebound in big-ticket items. The analyst said Costco is a high-conviction stock pick.
Telsey analyst Joseph Feldman called Costco's <a href="https://www.benzinga.com/25/04/44745979/costco-wholesale-posts-strong-march-sales-uptick-in-purchases-ahead-of-tariffs-analysts-say">March same-store sales </a>"impressive," ahead of the upcoming third-quarter results.
"Costco continues to execute well in this uncertain operating environment," Feldman said.
The analyst reiterated an Outperform rating and $1,100 price target after the March sales figures.
Key Items to Watch: Similar to other retail stocks, investors and analysts will likely be centered on any commentary and guidance that involves tariffs.
Costco was one of the early companies to address tariffs ahead of inauguration with the company discussing potential price increases due to tariffs from President Donald Trump.
&#8220;In general, of course, tariffs raise costs. That&#8217;s not something that we see as a positive in general," Costco Chief Financial Officer Gary Millerchip said at the time.
Millerchip said the company had plans in place to prevent possible price increases.
Trump's presidential transition team <a href="https://www.benzinga.com/trading-ideas/24/12/42536470/costco-warns-that-tariffs-raise-prices-trump-team-says-trade-policies-will-make-life-affordable">took exception</a> to the comments from Costco at the time and said Trump's economic and trade policies would make life affordable and more prosperous for the U.S.
Walmart recently reported financial results and said it may have to pass on higher costs to consumers. This comment angered Trump and led to the president telling the retailer to<a href="https://www.benzinga.com/markets/25/05/45536218/walmart-responds-to-trumps-eat-the-tariff-remark-worked-to-keep-our-prices-as-low-as-possible-and-we-wont-stop"> eat the costs.</a>
Costco may have to be cautious in what it says about price increases or face similar pushback from Trump.
The retailer reported positive year-over-year comparable sales for its U.S., Canada and other International segments in the second quarter. Investors and analysts will be watching to see if the momentum continues in the third quarter, along with the e-commerce segment sales.
A Placer.ai <a href="https://www.placer.ai/anchor/articles/wholesale-clubs-find-success-in-q1-2025">report </a>said Costco had visit growth of 2.3% in February, 7.8% in March and 3.4% in April on a year-over-year basis. The third-quarter results will include portions of February and May along with all of March and April.
In the report, Costco's visitor growth was higher than rivals BJ's Wholesale and Sam's Club, which could also indicate some market share gains in the quarter.
Another item investors and analysts could be watching is membership fee revenue. This figure came in at $1.19 billion in <a href="https://www.benzinga.com/news/earnings/25/03/44180426/costco-q2-earnings-revenue-beat-eps-miss-comps-up-6-8-driven-by-strength-in-the-us">the second quarter,</a> up from $1.11 billion in the prior year's second quarter. Costco raised the price of its annual store membership by five dollars in September 2024, a company first membership fee hike since 2017.
While membership fee is a small portion of overall revenue, it is high margin and recurring.
COST Price Action: Costco stock closed Wednesday down 0.46% to $1,013.14 on versus a 52-week trading range of $788.20 to $1,078.24. Costco stock is up 11.4% year-to-date in 2025 and up around 25% over the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44185877/costco-ceo-says-it-is-well-equipped-to-mitigate-trumps-tariffs-but-warns-of-inflation-impact-on-consumers-when-it-rains-it-rains-on-everyone">Costco CEO Says It Is &#8216;Well Equipped&#8217; To Mitigate Trump&#8217;s Tariffs, But Warns Of Inflation Impact On Consumers: &#8216;When It Rains, It Rains On Everyone&#8217;</a></li>
</ul>
Photo: Shutterstock

Previews

COST

Costco Wholesale Q3 Earnings Preview: Will Company Discuss Price Increases After Prior Trump Team Backlash?

Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) has outperformed the market over the past 20 years by 16.68% on an annualized basis producing an average annual return of 24.95%. Currently, Tyler Technologies has a market capitalization of $24.74 billion. 
Buying $1000 In TYL: If an investor had bought $1000 of TYL stock 20 years ago, it would be worth $87,578.63 today based on a price of $573.64 for TYL at the time of writing.
<h3>Tyler Technologies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748470511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Tyler Technologies 20 Years Ago Would Be Worth Today

HP Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) reported second-quarter financial results Wednesday after the bell. Here&#8217;s a look at the key highlights <a href="https://www.benzinga.com/pressreleases/25/05/g45656829/hp-inc-reports-fiscal-2025-second-quarter-results">from the period</a>.
Q2 Earnings: HP reported second-quarter revenue of $13.22 billion, beating analyst estimates of $13.15 billion. The company reported second-quarter adjusted earnings of 71 cents per share, missing estimates of 80 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;In&nbsp;Q2, we delivered solid revenue growth, led by strong Commercial performance in Personal Systems and continued momentum behind our future of work strategy,&#8221; said Enrique Lores, president and CEO of HP.
&#8220;While results in the quarter were impacted by a dynamic regulatory environment, we responded quickly to accelerate the expansion of our manufacturing footprint and further reduce our cost structure,&#8221; Lores noted.
Outlook: HP expects third-quarter adjusted earnings of 68 cents to 80 cents per share versus estimates of 90 cents per share. The company also lowered its full-year adjusted earnings outlook from a range of $3.45 to $3.75 per share to a new range of $3 to $3.30 per share. Analysts had been anticipating full-year adjusted earnings of $3.49 per share.
HP noted that its outlook&nbsp;reflects the added cost driven by the current U.S. tariffs in place.
HP Price Action: <a href="http://benzinga.com/quote/HPQ">HP shares</a> were down 12.54% in Wednesday&#8217;s after-hours session, trading at $23.79 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong">Nvidia Q1 Highlights: China Export Ban Hits Results But Jensen Huang Says Demand &#8216;Incredibly Strong&#8217;</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45657851/salesforce-q1-earnings-revenue-beat-eps-beat-raised-guidance-momentum-in-agentic-ai-shares-surge">Salesforce Q1 Earnings: Revenue Beat, EPS Beat, Raised Guidance, Momentum In Agentic AI, Shares Surge</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

Earnings

Guidance

Movers

Tech

HP Stock Tumbles As Q2 Earnings Fall Short Of Estimates, Guidance Comes In Soft Due To Higher Costs Related To Tariffs

WIIM

ELF stock has given up its prior loss. e.l.f. Beauty shares were trading lower following Q4 reported financial results.

Offerings

General

GANX

Gain Therapeutics Files For Mixed Shelf Offering Of $100M

UFCS

United Fire Group Files For Mixed Shelf; Size Not Disclosed

Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Jamf Holding, presenting an average target of $18.7, a high estimate of $27.00, and a low estimate of $13.00. Observing a downward trend, the current average is 7.88% lower than the prior average price target of $20.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469693_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Jamf Holding's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joey Marincek</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joey Marincek</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jamf Holding. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jamf Holding compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Jamf Holding's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Jamf Holding's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAMF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jamf Holding analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Jamf Holding</h2>
Jamf Holding Corp is the standard in Apple Enterprise Management, and its cloud software platform is the vertically focused Apple infrastructure and security platform. The company helps organizations, including businesses, hospitals, schools, and government agencies, connect, manage, and protect Apple products, apps, and corporate resources in the cloud without ever having to touch the devices. It sells its Software-as-a-Service, or SaaS, solutions via a subscription model, through a direct sales force, online, and indirectly via its channel partners, including Apple. The company operates in The Americas; Europe, the Middle East, India, and Africa; and Asia Pacific.
<h3>Jamf Holding: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jamf Holding's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 10.19%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Jamf Holding's net margin excels beyond industry benchmarks, reaching 0.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.07%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Jamf Holding's ROA stands out, surpassing industry averages. With an impressive ROA of 0.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Jamf Holding's debt-to-equity ratio is below the industry average. With a ratio of 0.5, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

JAMF

Where Jamf Holding Stands With Analysts

Phase 1/2 H5 avian flu vaccine study shows positive interim results
Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines
CAMBRIDGE, MA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 28, 2025 / Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) today announced positive interim data from a Phase 1/2 clinical study (<a href="https://pr.report/aw4q">NCT05972174</a>) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype.
The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines.

Biotech

MRNA

Moderna Reports Interim Phase 1/2 Results For H5 Avian Flu Vaccine mRNA-1018 In 300 Adults; HHS Terminates Award For Late-Stage Development And Pre-Pandemic Vaccine Purchase Rights

During the last three months, 19 analysts shared their evaluations of MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $165.79, a high estimate of $195.00, and a low estimate of $134.00. This current average reflects an increase of 1.56% from the previous average price target of $163.24. 
<img src="https://www.benzinga.com/files/images/story/2025/1748469673_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of MasTec by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$181.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$188.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$171.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$184.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$152.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$143.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$154.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$134.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$153.00</td>
<td>$162.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MasTec. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MasTec compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of MasTec's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of MasTec's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MTZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MasTec analyst ratings.</a>
<h2>Discovering MasTec: A Closer Look</h2>
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
<h3>MasTec: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, MasTec showcased positive performance, achieving a revenue growth rate of 5.99% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: MasTec's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.35%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.34%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.11%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: MasTec's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.91, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

19 Analysts Have This To Say About MasTec

Press Releases

Astrana Health Announces Definitive Agreement to Acquire Certain Businesses and Assets of Prospect Health System

Astrana Health Provider Groups Recognized with Highest Elite Status in America's Physician Groups 2024 Standards of Excellence™ Survey

Astrana Health, Inc. to Participate in Upcoming Investor Conference

Astrana Health, Inc. Announces Share Repurchase of 300,000 Shares

Astrana Health, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release and Conference Call

Astrana Health, Inc. to Participate in Upcoming Investor Conferences

Astrana Health, Inc. Reports Fourth Quarter and Year-End 2024 Results

Astrana Health, Inc. Schedules 2025 First Quarter Financial Results Release and Conference Call

Astrana Health, Inc. Reports First Quarter 2025 Results

ASTH

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Astrana Health

空売り

Astrana Health (NASDAQ:ASTH) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル